129 related articles for article (PubMed ID: 38171146)
1. Discovery of the cereblon-recruiting tubulin PROTACs effective in overcoming Taxol resistance in vitro and in vivo.
Yang H; Qin J; Pei Y; Guan S; Zhao M; Wang Y; Yao Y; Duan Y; Sun M
Eur J Med Chem; 2024 Feb; 265():116067. PubMed ID: 38171146
[TBL] [Abstract][Full Text] [Related]
2. Tubulin Resists Degradation by Cereblon-Recruiting PROTACs.
Gasic I; Groendyke BJ; Nowak RP; Yuan JC; Kalabathula J; Fischer ES; Gray NS; Mitchison TJ
Cells; 2020 Apr; 9(5):. PubMed ID: 32349222
[TBL] [Abstract][Full Text] [Related]
3. [Down-regulated βIII-tubulin expression can reverse paclitaxel resistance in A549/taxol cells lines].
Zhuo Y; Guo Q
Zhongguo Fei Ai Za Zhi; 2014 Aug; 17(8):581-7. PubMed ID: 25130963
[TBL] [Abstract][Full Text] [Related]
4. Effective degradation of EGFR
Qu X; Liu H; Song X; Sun N; Zhong H; Qiu X; Yang X; Jiang B
Eur J Med Chem; 2021 Jun; 218():113328. PubMed ID: 33773286
[TBL] [Abstract][Full Text] [Related]
5. Recent advancements in the discovery of cereblon-based protease-targeted chimeras with potential for therapeutic intervention.
Singh H; Agrawal DK
Future Med Chem; 2022 Oct; 14(19):1403-1416. PubMed ID: 36047364
[TBL] [Abstract][Full Text] [Related]
6. Discovery of novel BCR-ABL PROTACs based on the cereblon E3 ligase design, synthesis, and biological evaluation.
Liu H; Ding X; Liu L; Mi Q; Zhao Q; Shao Y; Ren C; Chen J; Kong Y; Qiu X; Elvassore N; Yang X; Yin Q; Jiang B
Eur J Med Chem; 2021 Nov; 223():113645. PubMed ID: 34217059
[TBL] [Abstract][Full Text] [Related]
7. Elevated levels of microtubule destabilizing factors in a Taxol-resistant/dependent A549 cell line with an alpha-tubulin mutation.
Martello LA; Verdier-Pinard P; Shen HJ; He L; Torres K; Orr GA; Horwitz SB
Cancer Res; 2003 Mar; 63(6):1207-13. PubMed ID: 12649178
[TBL] [Abstract][Full Text] [Related]
8. Antisense oligonucleotides to class III beta-tubulin sensitize drug-resistant cells to Taxol.
Kavallaris M; Burkhart CA; Horwitz SB
Br J Cancer; 1999 Jun; 80(7):1020-5. PubMed ID: 10362110
[TBL] [Abstract][Full Text] [Related]
9. Overcoming Taxol-resistance in A549 cells: A comprehensive strategy of targeting P-gp transporter, AKT/ERK pathways, and cytochrome P450 enzyme CYP1B1 by 4-hydroxyemodin.
Lin H; Hu B; He X; Mao J; Wang Y; Wang J; Zhang T; Zheng J; Peng Y; Zhang F
Biochem Pharmacol; 2020 Jan; 171():113733. PubMed ID: 31783010
[TBL] [Abstract][Full Text] [Related]
10. BZML, a novel colchicine binding site inhibitor, overcomes multidrug resistance in A549/Taxol cells by inhibiting P-gp function and inducing mitotic catastrophe.
Bai Z; Gao M; Zhang H; Guan Q; Xu J; Li Y; Qi H; Li Z; Zuo D; Zhang W; Wu Y
Cancer Lett; 2017 Aug; 402():81-92. PubMed ID: 28576750
[TBL] [Abstract][Full Text] [Related]
11. Sulforaphane metabolites reduce resistance to paclitaxel via microtubule disruption.
Wang Y; Zhou Y; Zheng Z; Li J; Yan Y; Wu W
Cell Death Dis; 2018 Nov; 9(11):1134. PubMed ID: 30429459
[TBL] [Abstract][Full Text] [Related]
12. Solid-Phase Synthesis of Cereblon-Recruiting Selective Histone Deacetylase 6 Degraders (HDAC6 PROTACs) with Antileukemic Activity.
Sinatra L; Yang J; Schliehe-Diecks J; Dienstbier N; Vogt M; Gebing P; Bachmann LM; Sönnichsen M; Lenz T; Stühler K; Schöler A; Borkhardt A; Bhatia S; Hansen FK
J Med Chem; 2022 Dec; 65(24):16860-16878. PubMed ID: 36473103
[TBL] [Abstract][Full Text] [Related]
13. Discovery of IAP-recruiting BCL-X
Zhang X; He Y; Zhang P; Budamagunta V; Lv D; Thummuri D; Yang Y; Pei J; Yuan Y; Zhou D; Zheng G
Eur J Med Chem; 2020 Aug; 199():112397. PubMed ID: 32388279
[TBL] [Abstract][Full Text] [Related]
14. Disordered region of cereblon is required for efficient degradation by proteolysis-targeting chimera.
Kim K; Lee DH; Park S; Jo SH; Ku B; Park SG; Park BC; Jeon YU; Ahn S; Kang CH; Hwang D; Chae S; Ha JD; Kim S; Hwang JY; Kim JH
Sci Rep; 2019 Dec; 9(1):19654. PubMed ID: 31873151
[TBL] [Abstract][Full Text] [Related]
15. Discovery of E3 Ligase Ligands for Target Protein Degradation.
Lee J; Lee Y; Jung YM; Park JH; Yoo HS; Park J
Molecules; 2022 Oct; 27(19):. PubMed ID: 36235052
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and Evaluation of Cereblon-Recruiting HaloPROTACs.
Ody BK; Zhang J; Nelson SE; Xie Y; Liu R; Dodd CJ; Jacobs SE; Whitzel SL; Williams LA; Gozem S; Turlington M; Yin J
Chembiochem; 2023 Nov; 24(21):e202300498. PubMed ID: 37625128
[TBL] [Abstract][Full Text] [Related]
17. Target protein localization and its impact on PROTAC-mediated degradation.
Simpson LM; Glennie L; Brewer A; Zhao JF; Crooks J; Shpiro N; Sapkota GP
Cell Chem Biol; 2022 Oct; 29(10):1482-1504.e7. PubMed ID: 36075213
[TBL] [Abstract][Full Text] [Related]
18. CRBN ligand expansion for hematopoietic prostaglandin D
Osawa H; Kurohara T; Ito T; Shibata N; Demizu Y
Bioorg Med Chem; 2023 Apr; 84():117259. PubMed ID: 37018877
[TBL] [Abstract][Full Text] [Related]
19. Modeling the CRL4A ligase complex to predict target protein ubiquitination induced by cereblon-recruiting PROTACs.
Bai N; Riching KM; Makaju A; Wu H; Acker TM; Ou SC; Zhang Y; Shen X; Bulloch DN; Rui H; Gibson BW; Daniels DL; Urh M; Rock BM; Humphreys SC
J Biol Chem; 2022 Apr; 298(4):101653. PubMed ID: 35101445
[TBL] [Abstract][Full Text] [Related]
20. Development of decoy oligonucleotide-warheaded chimeric molecules targeting STAT3.
Shih PC; Naganuma M; Tsuji G; Demizu Y; Naito M
Bioorg Med Chem; 2023 Nov; 95():117507. PubMed ID: 37922656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]